Selank is a synthetic tuftsin-derived heptapeptide studied in neuropeptide, immune-signaling, and behavioral-model research. The original overview of this page asks three questions: tuftsin-derived sequence design, separation of behavioral and immune-model endpoints, and sequence identity and purity controls for the lot on the bench.
Editorial review: 17 November 2026. Prepared by Velnacor Research Desk for research-use communication only. Published findings below are attributed to the cited papers. They are not claims about a Velnacor lot and are not instructions for use in people or animals.
Tuftsin-derived sequence design
Kasian and colleagues described Selank as including a short fragment of human immunoglobulin G heavy chain, Thr-Lys-Pro-Arg (tuftsin), elongated at the C terminus with Pro-Gly-Pro, and their methods name the material as the Nα-Thr-Lys-Pro-Arg-Pro-Gly-Pro diacetate salt (Kasian et al., 2017). Vyunova and colleagues likewise discussed Selank as a heptapeptide in a review of molecular aspects of its reported biological activity (Vyunova et al., 2018). That sequence language should appear consistently on the brief, the quotation, and the report. Selank is not tuftsin alone, and it is not Semax, an ACTH(4-10) analogue. A Semax identity note is at What Is Semax?; a comparison of the two names is at Semax vs Selank.
Behavioral-model findings — and their limits
In rats, Kasian and colleagues evaluated Selank and diazepam, alone and together, in the elevated plus-maze, both without chronic stress and after unpredictable chronic mild stress. They reported that, under chronic stress, anxiety-related measures after the simultaneous use of diazepam and Selank did not differ from the values observed before stress exposure, and they discussed differences between individual and combined administration in the designs they used (Kasian et al., 2017). Those are rodent behavioral observations. They are not a clinical anxiolytic claim, they are not a use instruction, and they should not be transferred automatically to Semax or to unmodified tuftsin.
Vyunova and colleagues reviewed molecular aspects of Selank’s reported activity and contrasted peptide research in this area with commonly used agents that act on GABA-receptor systems (Vyunova et al., 2018). That article is a review, not a new controlled trial, and this page does not adopt “anxiolytic” as a product or clinical claim. Immune-signaling questions, if they appear in a protocol, belong in their own endpoint list rather than being inferred from a behavioral assay.
Identity, purity, and documentation
Behavioral and immune-model endpoints, if both appear in a file, should be specified separately. A useful quality review still separates sequence identity, purity, content, and lot matching for this short peptide. What Is a Peptide COA?, How to Read a Peptide COA, HPLC vs Mass Spectrometry for Peptide Lot Review, Third-Party Peptide Testing, Explained, and lot traceability apply here as they do to other research peptides.
Selank appears in Velnacor’s research-material catalog (internal product record, slug selank), as does a combination SKU with Semax. There is not a standalone public landing page for every catalog name; use the product directory and the COA Library, then confirm the exact SKU and current-lot documents in the inquiry. Combination presentations, if purchased, need their own identifiers and should not borrow a Selank-only report. For packing at supply scale, see wholesale peptides.
Selected published literature
- Kasian A, Kolomin T, Andreeva L, Bondarenko E, Myasoedov N, Slominsky P, Shadrina M. Peptide Selank enhances the effect of diazepam in reducing anxiety in unpredictable chronic mild stress conditions in rats. Behavioural Neurology. 2017;2017:5091027. doi:10.1155/2017/5091027. PubMed 28280289.
- Vyunova TV, Andreeva L, Shevchenko K, Myasoedov N. Peptide-based anxiolytics: the molecular aspects of heptapeptide Selank biological activity. Protein & Peptide Letters. 2018;25(10):914-923. doi:10.2174/0929866525666180925144642. PubMed 30255741. Review article; cited for heptapeptide identity, not as a use instruction.
Sourcing notes for qualified buyers
Velnacor’s stated supply terms for qualified research and business buyers include: every batch is third-party tested; orders usually ship within 24 hours, subject to stock, documentation review, and destination; trial orders can start from one box of ten vials; parcels lost or damaged in transit are eligible for free reshipment or a refund; and neutral packaging is available when required. Velnacor operates its own production base and has a long-standing supply-chain business.
Those points describe documentation and fulfillment. They do not describe a laboratory or biological outcome. For an order-specific review, send the material name, specification, box quantity, and destination through the inquiry list.
Research-use notice. All Velnacor products are intended strictly for laboratory research use only. They are not drugs, supplements, or food, and are not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary use. Purchasers must be qualified researchers. This article is educational content for laboratory and business readers. It does not provide dosing, reconstitution, administration, diagnostic, or treatment guidance.